New biosimilar version of arthritis drug etanercept launches in UK
An affordable new therapy option for people with various forms of arthritis has been launched in the UK.Benepali is the first biosimilar version of the established anti-TNF therapy etanercept to be released in Britain, following its approval by the European Commission last month. Its availability is expected to expand access to anti-TNF therapy and ensure patients can be treated more cost-effectively.How Benepali works Biosimilars are a class of drugs that function as near-identical copies of established products that are already available on the market. They seek to replicate the effects and function of the reference prod...
Source: Arthritis Research UK - February 19, 2016 Category: Rheumatology Source Type: news
What Really Killed Glenn Frey
When Glenn Frey, a co-founder and driving force behind ’70s supergroup the Eagles, died on January 18, I wasn’t just saddened by the loss. I was deeply concerned about the manner of his death.
News reports said Frey died from a combination of “complications” from rheumatoid arthritis (RA), one of the most debilitating chronic diseases.
RA is an inflammatory autoimmune condition. It affects the entire body — particularly the joints. The body develops antibodies against its own joint tissues, breaking them down.
A modern inflammatory diet, genetic factors and food allergies all play a role in developing RA. Envir...
Source: Al Sears, MD Natural Remedies - February 16, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Men's Health arthritis inflammation vitamin D3 Vitamin K2 Source Type: news
New drugs recommended for ankylosing spondylitis and nr-axSpA treatment in the NHS
The National Institute for Health and Care Excellence (NICE) is a government body that decides which drugs and treatments are available on the NHS in England and Wales.
A number of anti-TNF therapies have now been recommended for use within the NHS as treatments for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis (nr-axSpA). Non-radiographic axial spondyloarthritis differs from ankylosing spondylitis, as there is no X-ray evidence of structural damage, meaning it can often go unrecognised for years.
New guidance issued by NICE has endorsed the therapies as options for patients who have fai...
Source: Arthritis Research UK - February 15, 2016 Category: Rheumatology Source Type: news
Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $10.38
2015 GAAP EPS Were $9.06
2016 Total Revenues and Adjusted EPS Guidance Increased to $22.0-$22.5 Billion and $10.60-$11.00, Respectively
THOUSAND OAKS, Calif., Jan. 28, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2015. Key results include:
For the fourth quarter, total revenues increased 4 percent to $5,536 million, with 3 percent product sales growth driven by Enbrel® (etanercept), Sensipar® (cinacalcet), Prolia® (denosumab), Kyprolis® (carfilzomib) and XGEVA® (denosumab). Adjusted operating income grew 16 percent to $2,366 million and...
Source: Amgen News Release - January 28, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
New biosimilar version of etanercept approved in Europe
An affordable new treatment for various types of arthritis is to be made available in Europe following the approval of the drug Benepali.The new biosimilar version of the anti-TNF therapy etanercept has been granted marketing authorisation in the EU for the treatment of adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis and plaque psoriasis.Developed by Samsung Bioepis, the drug is the first etanercept biosimilar to be based on the licensed product Enbrel, and will become the first subcutaneous anti-TNF biosimilar to be launched in Europe.Biosimilars are biolo...
Source: Arthritis Research UK - January 19, 2016 Category: Rheumatology Source Type: news
BENEPALI(R), the First Etanercept Biosimilar Referencing Enbrel(R), Approved in the European Union
Biogen will manufacture and commercialize BENEPALI in the EU
ZUG, Switzerland--(Healthcare Sales & Marketing Network)--The joint venture between Biogen (BIIB) and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for... Biopharmaceuticals, RegulatoryBiogen, Samsung BioLogics, biosimilar, BENEPALI, Etanercept, arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 17, 2016 Category: Pharmaceuticals Source Type: news
Samsung Bioepis' Enbrel drug copy gets EU approval
SEOUL (Reuters) - Samsung Bioepis Co Ltd said on Sunday it had received European Commission approval for its copy of the blockbuster biotech arthritis drug Enbrel. (Source: Reuters: Health)
Source: Reuters: Health - January 17, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Samsung Gets European Approval for Enbrel Copy
Samsung Group said it has won approval from regulators to sell a near-replica of the blockbuster rheumatoid arthritis drug Enbrel in Europe. (Source: WSJ.com: Health)
Source: WSJ.com: Health - January 17, 2016 Category: Pharmaceuticals Tags: PAID Source Type: news
Kids With Arthritis Can Do Well on Enbrel (CME/CE)
(MedPage Today) -- Almost half had minimal disease activity by 1 year (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - January 15, 2016 Category: Pediatrics Source Type: news
An Update on BiosimilarsAn Update on Biosimilars
Biosimilars to adalimumab, etanercept, and infliximab measure up safety and efficacy-wise for rheumatology patients inadequately responsive to methotrexate. Medscape Rheumatology (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - December 9, 2015 Category: Rheumatology Tags: Rheumatology Commentary Source Type: news
First Enbrel Biosimilar Recommended for Approval in EuropeFirst Enbrel Biosimilar Recommended for Approval in Europe
The EMA has recommended Benepali, an etanercept biosimilar for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 20, 2015 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news
EU endorses copy of Enbrel arthritis drug from Samsung, Biogen
LONDON (Reuters) - A copy of the blockbuster biotech drug Enbrel was recommended for approval in Europe on Friday, making it the second so-called biosimilar antibody medicine to win such a green light from the continent's regulators. (Source: Reuters: Health)
Source: Reuters: Health - November 20, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Europe could recommend second biosimilar arthritis drug this week
LONDON (Reuters) - Europe could soon gain a second biosimilar antibody drug for rheumatoid arthritis and other autoimmune diseases, with regulators due to decide by Friday whether to recommend South Korean company Samsung Bioepis's copy of Enbrel. (Source: Reuters: Health)
Source: Reuters: Health - November 18, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
